Rao Vallabhaneni, Liverpool, UK, presented data from the BSET study. He told CX delegates the study set out to investigate what the magnitude of early benefit from the procedure was (for instance, a decrease in death); measure how long this lasts and what the target vessel patency is.
The study included all fenestrated EVAR procedures done between 2007 and 2010. Data were included from centres that have done more than 10 procedures and branched EVAR cases were not included. Data were collected online, Vallabhaneni said.
“Three hundred and eighteen patients (of which two were unsuccessful) were treated. The mean age was 74 years (47–86). The mean aneurysm size was 65mm (46–113). Cook stent grafts were used in all cases,” he said.
The analysis showed that combined in-hospital and 30-day mortality was 4.1%. There was approximately a 7% absolute risk reduction, he noted. “The complexity of the case was not related to the risk of death; the target vessel patency was acceptable, as serious consequences of target vessel loss is rare and the broad application appears justified,” Vallabhaneni said.
